A Retrospective Study of Prognostic Factors and Survival of Breast Cancer Patients With Brain Metastesis

Breast cancer (BC) has become the malignancy with the highest morbidity rate in women. Despite significant advances in the diagnosis and treatment of breast cancer, metastasis is still an important factor that seriously affects patients' quality of life and prognosis. It has been reported that distant metastases have been found at the initial diagnosis of breast cancer in about 6-10% of patients The bones, lungs, liver and brain are the four most common distant metastatic sites of breast cancer Compared with bone metastases and visceral metastases, patients with brain metastases have significantly worse prognosis The median time from diagnosis of breast cancer to CNS metastasis has been reported to be 33 month The survival of these patients may be affected by factors including molecular subtypes, performance status, ressectability of BM and visceral metastasis burden. When detected, its treatment is usually difficult and unfortunately has reverse effects on life expectancy Multi-disciplinary therapy (MDT) is the first choice for the treatment of brain metastases in breast cancer MDT for breast cancer brain metastasis includes surgery, whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), chemotherapy, endocrine therapy, targeted therapy, etc. For patients with multiple brain metastases and neurological symptoms, WBRT combined with palliative care is the preferred option In general, patients with brain metastases of 3 or less were recommended to receive surgical resection. Patients with 4 to 5 brain metastases but less 3cm in diameter can undergo SRS .

Inclusion criteria

• -Age >18
• Histological proven breast cancer
• Radiological documentation of BM by computed tomography (CT) OR magnetic resonance imaging (MRI)
• Patients who had been followed up for at least 6 months.

Exclusion criteria

• -Not histologically proven Breast cancer
• Patient without full medical data
• Those with previous or concurrent diagnosis of second primary malignancy
• Patients with leptomeningeal or dural metastases without co-existent parenchymal metastatic lesions